Edition:
United States

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

9.14EUR
19 Feb 2018
Change (% chg)

-- (--)
Prev Close
€9.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
211,981
52-wk High
€13.68
52-wk Low
€7.65

Select another date:

Tue, Dec 19 2017

BRIEF-Nicox Updates on Drug Development And Outlines 2018 Activities

* RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT

BRIEF-Bausch + Lomb and Nicox announces FDA approval of Vyzulta

* Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

BRIEF-‍Nicox enters research collaboration with Re-Vana Therapeutics

* ‍Nicox enters research collaboration with Re-Vana Therapeutics on its next generation of stand-alone no-donors in a novel sustained release ophthalmic formulation​

BRIEF-Nicox and pSivida enter strategic collaboration agreement

* REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA

BRIEF-Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​

* Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​

BRIEF-Nicox announces licensing agreement with Eyevance

* ANNOUNCES LICENSING AGREEMENT WITH EYEVANCE FOR COMMERCIALIZATION OF ZERVIATETM IN UNITED STATES

BRIEF-Nicox H1 operating loss narrows to ‍​11.6 million euros

* ‍ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% NEW DRUG APPLICATION (NDA) APPROVED​

Select another date: